Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Racemethorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A known ✓ | Q12879 | 8/20 | 1.00 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 6/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 8/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 7/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 7/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 7/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 7/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 7/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 7/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racemethorphan SCHEMBL503864 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Dextromethorphan SCHEMBL29949 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levomethorphan SCHEMBL29950 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL22722074 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL4167360 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL14579836 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL20808854 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL20809259 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL21095577 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL12091342 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1718 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440489-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-10-14 | — | — | US | claimed |
| US-20240207369-A1 | In Vitro Drugs from Prodrugs and Use Thereof | BRANDENBURGISCHE TECHNISCHE UNIVERSITAT COTTBUS-SENFTENBERG (DE) | 2024-06-27 | — | — | US | claimed |
| US-20240165022-A1 | Pharmaceutical Formulation | KLARIA PHARMA HOLDING AB (SE) | 2024-05-23 | — | — | US | claimed |
| US-20240165111-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-05-23 | — | — | US | claimed |
| US-20240083877-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | PURDUE RESEARCH FOUNDATION (US) | 2024-03-14 | — | — | US | claimed |
| EP-4330382-A2 | IN VITRO DRUGS FROM PRODRUGS AND USE THEREOF | Brandenburgische Technische Universität Cottbus-Senftenberg (DE) | 2024-03-06 | — | — | EP | claimed |
| US-11904049-B2 | Pharmaceutical formulation | KLARIA PHARMA HOLDING AB (SE) | 2024-02-20 | — | — | US | claimed |
| US-11844757-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-12-19 | — | — | US | claimed |
| US-20230390281-A1 | OPIOID FOR USE TO REDUCE AND/OR DRUG ADDICTION | DMK PHARMACEUTICALS CORPORATION | 2023-12-07 | — | — | US | claimed |
| US-11779581-B2 | Opioid for use to reduce and/or treat drug addiction | DMK PHARMACEUTICALS CORPORATION (US) | 2023-10-10 | — | — | US | claimed |
| US-6319954-B1 | ADMINISTERED TO TREAT ONE OR MORE WITHDRAWAL SYMPTOMS RESULTING FROM AN ADDICTIVE PSYCHOSTIMULANT. | SOMERSET PHARMACEUTICALS, INC. | 2001-11-20 | — | — | US | claimed |
| US-6299901-B1 | ADMINISTERING R(-)DESMETHYLSELEGILINE USING DOSAGE REGIMEN TO TREAT ONE OR MORE WTHDRAWAL SYMPTOMS ASSOCIATED WITH ONE OR MORE DRUGS SELECTED FROM ADDICTIVE PSYCHOSTIMULANTS, OPIATES, NARCOTICS, BARBITURATES, ALCOHOL, AND NICOTINE | SOMERSET PHARMACEUTICALS, INC. | 2001-10-09 | — | — | US | claimed |
| US-20010018457-A1 | Desmethylselegiline enantiomers and their use to treat drug withdrawal symptoms | DISANTO ANTHONY R (US) | 2001-08-30 | — | — | US | claimed |
| WO-2000071109-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING S-(+) -DESMETHYLSELEGILINE FOR THE TREATMENT OF WITHDRAWAL | SOMERSET PHARMACEUTICALS, INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-5654281-A | Inhibiting the development of tolerance to and/or dependence on an addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-08-05 | — | — | US | claimed |
| US-5556838-A | BLOCKING N-METHYLASPARTATE RECEPTORS TO PREVENT ADDICTION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1996-09-17 | — | — | US | claimed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | claimed |
| US-5321012-A | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL COLLEGE (US) | 1994-06-14 | — | — | US | claimed |
| EP-0387068-A1 | Improving the enantioselectivity of biocatalytic resolution of racemic compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1990-09-12 | — | — | EP | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083877-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | CAP1, ADCY1, ADCYAP1R1 | GRIN2A 358/4885SIGMAR1 196/4885GRIN1 36/4885 |
| US-11779581-B2 | Opioid for use to reduce and/or treat drug addiction | OPRM1, OPRK1, OPRD1 | GRIN2A 87/4885SIGMAR1 5/4885GRIN1 102/4885 |
| US-20240165111-A1 | ORGANIC COMPOUNDS | HTR2C, HTR2A, HTR3A | GRIN2A 56/4885SIGMAR1 35/4885GRIN1 251/4885 |
| US-20230390281-A1 | OPIOID FOR USE TO REDUCE AND/OR DRUG ADDICTION | OPRM1, OPRK1, OPRD1 | GRIN2A 66/4885SIGMAR1 5/4885GRIN1 92/4885 |
| US-20010018457-A1 | Desmethylselegiline enantiomers and their use to treat drug withdrawal symptoms | UGT2B7, UGT1A7, PNMT | GRIN2A 47/4885SIGMAR1 672/4885GRIN1 137/4885 |
| US-11844757-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | GRIN2A 49/4885SIGMAR1 7/4885GRIN1 107/4885 |
| US-12440489-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | GRIN2A 49/4885SIGMAR1 7/4885GRIN1 107/4885 |
| US-11904049-B2 | Pharmaceutical formulation | OGFR, OPRL1, OPRM1 | GRIN2A 208/4885SIGMAR1 39/4885GRIN1 278/4885 |
| US-20240207369-A1 | In Vitro Drugs from Prodrugs and Use Thereof | CYP3A5, CYP3A4, CYP2D6 | GRIN2A 3738/4885SIGMAR1 840/4885GRIN1 4039/4885 |
| US-20240165022-A1 | Pharmaceutical Formulation | OGFR, OPRL1, OPRM1 | GRIN2A 208/4885SIGMAR1 39/4885GRIN1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.